+++ Wer jetzt gleich mit einsteigt +++ hat gute Chancen - 500 Beiträge pro Seite

[MCGabriel]

auf Zig-Prozente in den nächsten Monaten

PR NEWSWIRE) LAM Pharmaceutical Announces Extension of Product Shelf Life
LAM Pharmaceutical Announces Extension of Product Shelf Life

LEWISTON, N.Y., Dec. 11 /PRNewswire-FirstCall/ -- LAM Pharmaceutical,
Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical
company focused on the development and commercialization of novel wound
healing and transdermal drug delivery systems, announced today that the shelf
life of its IPM Wound Gel has been extended to three years. LAM has
successfully completed all testing, analysis and documentation required
pursuant to consultations with the U.S. Food and Drug Administration (FDA) in
order to extend IPM Wound Gel shelf life from eighteen months to thirty-six
months.
" The extended shelf life provides LAM with increased flexibility in
production and distribution. LAM is positioned to achieve improved cost
efficiencies as sales increase," commented Joseph Slechta, President and Chief
Executive Officer of LAM. " LAM IPM Wound Gel is continuing to receive
excellent feedback from the medical community. An increasing number of
hospitals and wound care professionals are utilizing the wound gel as LAM
continues its marketing efforts."

About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company
with laboratories in Lewiston, New York, and a business office in Toronto. LAM
focuses on the development and commercialization of novel wound healing and
(PR NEWSWIRE) LAM Pharmaceutical Announces Extension of Product Shelf Life
LAM Pharmaceutical Announces Extension of Product Shelf Life

LEWISTON, N.Y., Dec. 11 /PRNewswire-FirstCall/ -- LAM Pharmaceutical,
Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical
company focused on the development and commercialization of novel wound
healing and transdermal drug delivery systems, announced today that the shelf
life of its IPM Wound Gel has been extended to three years. LAM has
successfully completed all testing, analysis and documentation required
pursuant to consultations with the U.S. Food and Drug Administration (FDA) in
order to extend IPM Wound Gel shelf life from eighteen months to thirty-six
months.
" The extended shelf life provides LAM with increased flexibility in
production and distribution. LAM is positioned to achieve improved cost
efficiencies as sales increase," commented Joseph Slechta, President and Chief
Executive Officer of LAM. " LAM IPM Wound Gel is continuing to receive
excellent feedback from the medical community. An increasing number of
hospitals and wound care professionals are utilizing the wound gel as LAM
continues its marketing efforts."

About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company
with laboratories in Lewiston, New York, and a business office in Toronto. LAM
focuses on the development and commercialization of novel wound healing and
transdermal drug delivery systems that offer patients, among other benefits,
safer and more effective treatment for a variety of serious diseases. The
technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology
(L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S.
issued and approved patents) of electrically charged and non-charged molecules
with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate
for use with well-established drugs, allowing for the sustained delivery of
greater amounts to the target areas than is otherwise possible by oral means,
thus prolonging therapeutic activity.

Statements in this press release regarding our business which are not
historical facts are " forward-looking statements" that involve risks and
uncertainties which could cause the Company`s actual results and financial
condition to differ materially from those anticipated by the forward-looking
statements. These risks and uncertainties include, but are not limited to
uncertainties relating to the need for additional funds and corporate
partners, product liability, dependence on third parties for manufacturing and
marketing, the early stage of products being marketed or under development,
patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are
trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following
patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington (Investors/Media)
646-536-7017
The Ruth Group

SOURCE LAM Pharmaceutical, Corp.
-0- 12/11/2003
/CONTACT: Investors-Media - Stephanie Carrington of The Ruth Group,
[phone], for LAM Pharmaceutical, Corp./
/Web site: http://www.lampharm.com /
(LAMP)

CO: LAM Pharmaceutical, Corp.
ST: New York
IN: BIO HEA MTC OTC
SU:

[MCGabriel]

Die letzten News sind eigentlich noch gar nicht so richtig angenommen worden

Thursday, 4. December 2003 | 08:05 Uhr [Artikel versenden] [Artikel drucken] [zurück]

IR-WORLD-Presse: L.A.M. Pharmaceutical CORP.: L.A.M. Pharmaceutical gibt Vertriebsvereinbarung bekannt


L.A.M. Pharmaceutical gibt ein Vertriebsvereinbarung für Lateinamerika bekannt

LEWISTON, N.Y., -- LAM Pharmaceutical, Corp. (WKN 631629) ein in der Biomedizin tätiges Unternehmen mit der Konzentration auf die Entwicklung und Kommerzialisierung eines neuen Wundheilung- und transdermalen Verabreichungssystems, gibt heute die Unterzeichnung einer umfangreichen Vertriebsvereinbarung mit der in Mexiko City ansässigen Verus S.A. de C.V. bekannt. Gemäß den Bedingungen der Vereinbarung wird Verus der exklusive Vertriebshändler des LAM IPM Wundgels in Zentral- und Südamerika, mit Ausnahme von Mexiko, Brasilien und Argentinien.

Joseph Slechta, President und CEO von LAM kommentierte: „Verus verfügt über eine umfassende Expertise in dem Vertrieb von Gesundheitsprodukten in Lateinamerika. Diese wichtige Bindung wird es LAM ermöglichen, diesen Wachstumsmarkt äußerst effektiv zu penetrieren. Die Vor-Ort-Präsenz der Mitarbeiter von Verus auch in den kleineren Ländern in der Region, erlaubt es LAM sich diese Nischenmärkte kosteneffektiv zu erschließen.

Joseph Slechta schloss: Dies ist ein weiterer Schritt in der langfristigen Strategie von LAM sich zu einer diversifizierten Healthcare-Firma mit einer starken internationalen Präsenz zu entwickeln.

Dr. Daniel Bagi, President und CEO von Verus fügte hinzu: „Wir sind überzeugt, einen wichtigen Beitrag zu die laufenden internationalen Marketingbemühungen von LAM zu leisten. Das LAM IPM Wundgel wird zu einem etablierten Wundheilungsprodukt und stellt einen hochinteressanten Zugang zu unserer Produktreihe dar.“

[MCGabriel]

Oder die mit Ixora

Press Release Source: LAM Pharmaceutical, Corp.


LAM Pharmaceutical and Ixora Bio Medical Announce The Launch of Ixora`s First Product
Tuesday November 25, 7:02 am ET


LEWISTON, N.Y., Nov. 25 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Ixora Bio Medical Company Inc., a licensee of LAM, is poised to commence marketing and commercial sales of " Ixora(TM) for Women" , a non-prescription female sexual enhancement product Ixora has licensed from LAM.
ADVERTISEMENT


John Easton, Chief Executive Officer of Ixora Bio Medical, stated, " The impending launch of `Ixora(TM) for Women` represents a major milestone for us. It is the culmination of four years of extensive research and development, clinical studies and marketing research. `Ixora(TM) for Women` is the first of several products addressing sexual dysfunction in both men and women based on LAM IPM Ionic Polymer Matrix platform that Ixora has licensed from LAM. It will be marketed and sold as a sophisticated, upscale sexual enhancement product, addressing the difficulties associated with female sexual function disorders. The Journal of the American Medical Association has stated that 43.0% of American women have faced at least one sexual function issue. These statistics are based on a national sampling of women ages 18-59."

Mr. Easton added, " In preparation for the launch, Ixora has assembled a group of first class professionals including a medical advisory board as well as branding, marketing and public relations teams. Ixora Bio Medical has established a network of sales outlets throughout North America for its `Ixora(TM) for Women` and has contracted manufacturing to a leading New Jersey based FDA approved GMP manufacturing facility."

Joseph Slechta, President and Chief Executive Officer of LAM, remarked, " We are very pleased about our licensee`s achievement. Ixora has had our total support throughout the commercialization stage. We will work with Ixora`s marketing team to ensure the successful launch of its first product. LAM anticipates royalty revenues from `Ixora(TM) for Women` to commence in the first half of 2004."

Mr. Slechta concluded, " The upcoming launch of `Ixora(TM) for Women` is particularly timely. The subject of human sexuality has come to the forefront in recent years and we are proud that Ixora has the opportunity to make a major positive contribution to this field."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About Ixora Bio Medical Company Inc.

Ixora Bio Medical Company is a biomedical company with headquarters in New York City. Ixora holds a world wide exclusive license from LAM for sexual dysfunction products based on LAM`s patented proprietary IPM Ionic Polymer Matrix transdermal delivery platform. The Company`s current focus is to develop and commercialize sexual enhancement products. More information about Ixora can be obtained by visiting www.Ixoraforwomen.com.

Statements in this press release regarding our business which are not historical facts are " forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.




--------------------------------------------------------------------------------
Source: LAM Pharmaceutical, Corp.

[MCGabriel]

Jetzt wird aber gekauft Kurs schon 0.16 in Fra

Plus 14 %

ASK 0.165

[MCGabriel]

Tageshoch 0.164 Plus 17%

[MCGabriel]

Jetzt wird wieder gewartet, bis der Kurs davonläuft

An alle - bin hier länger drin und möchte nicht pushen, sondern nur darauf aufmerksam machen, daß es hier zu Vervielfachungen kommen kann in den nächsten 24 Monaten

[Paepstin]

[goodbuy2003]

Zeig mir mal bitte einer ein Bild von IXORAS Zauberstift. Ich möchte doch auch endlich mal sehen wie das Teil in "echt" aussieht.

[lembi]

Ach du hast schon wieder eine völlig unterbewerte Aktie entdeckt

und jetzt willst du, (natürlich ohne eigenes Interesse)
dass alle anderen mitverdienen

ich denke es wird so laufen wie immer!!!

Gruß Lembi

[MCGabriel]

In Lamp bin ich schon lange Lembi

Kauf Dir lieber ein paar. Sind noch günstig im Moment

[fonx]

[suncomesout]

SCO